How to predict the market trend for the New Year? How to strategize for opportunities next year? The strategies from the top ten securities firms are here.

The latest strategic viewpoints from the top ten securities firms have just been released, with CITIC Securities suggesting to seek intersections in configuration, namely using overseas exposure as the base and actively changing domestic demand that will also generate catalytic varieties.

7 h ago

Hong Kong-listed company 18C Corporation is making waves in the Physical AI sector by holding a hearing on May 1st.

Recently, the Hong Kong Stock Exchange disclosed that Beijing Wuyi Vision Digital Twin Technology Co., Ltd. has passed the listing hearing and will impact Physical AI's first stock with 18C articles of association. China International Capital Corporation and Huatai International serve as joint sponsors.

8 h ago

FENBI (02469) partners with Huatu strategically to reshape the valuation logic of top-level collaboration in vocational education.

On December 14, the top two enterprises in the field of vocational education, Chalk and Huatu Shanding, announced a deep strategic cooperation, aiming to promote resource integration in terms of service depth, cost structure, and business expansion, and jointly draw up a new blueprint for the high-quality development of vocational education.

8 h ago

FENBI (02469) and Huatu have reached a strategic cooperation agreement to consolidate their leading positions in the industry.

Chalk (02469) announced that on December 12, 2025 (trading hours), the company entered into a strategic cooperation agreement with Huatu Shanding Design Co., Ltd. (Huatu). According to the strategic cooperation agreement, both parties agreed to establish a strategic partnership, leverage each other's complementary advantages, and enhance the overall competitiveness of both parties. The parties aim to jointly explore the following areas of cooperation in the exam training business: 1. Investment cooperation; 2. Corporate governance; 3. Technology development; 4. Distribution channel cooperation; 5. Industry self-discipline; 6. Customer service.

8 h ago

PEGBIO CO-B(02565) intends to discount 10% for a total of 5.136 million shares issued for sale, raising approximately HK$296 million.

Paige Biopharmaceuticals-B (02565) announced that on December 12, 2025 (after trading hours), the company entered into a placement agreement with joint placing agents. Pursuant to this, the company has conditionally agreed to place a total of 5,136,000 shares at a price of HK$58.41 per share to not less than six placees through the joint placing agents on a best efforts basis. These placement shares will be issued by the company under the general mandate in accordance with the terms and conditions of the placement agreement.

8 h ago

Viva Biotech (01873) sold its equity to an investment incubator company.

Viva Biotech (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer Sobi US Holding Corp. has agreed to acquire Arthrosi Therapeutics through a merger. Upon completion, the company will no longer hold any equity in Arthrosi Therapeutics. The prepayment specified in the merger agreement at completion is $950 million (subject to customary adjustments) and a contingent consideration not exceeding $550 million.

9 h ago

October net purchases of 49 tons! The central bank's purchase of gold remains strong. Goldman Sachs: "Tokenized gold" is not currently the main driver of gold prices.

Goldman Sachs estimates that global central banks still net bought 49 tons of gold in the market's sharp volatility in October, far exceeding the previous average monthly level of 17 tons, and is seen as a long-term strategy to hedge risks.

9 h ago

JUNSHI BIO (01877): The clinical trial application for JS212 for the treatment of advanced solid tumors has been approved by the FDA.

Junshi Biosciences (01877) announced that the company has received notification from the Food and Drug Administration (FDA) in the United States that the clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.

9 h ago

DL Holdings GP (01709) is deploying highly efficient mining hardware in selected overseas mining fields to continue actively developing and expanding institutional-level Bitcoin mining business.

Delin Holdings (01709) announced that the company will deploy efficient mining hardware in selected overseas mines in the United States, Oman, and Paraguay, to continue actively developing and expanding institutional-grade Bitcoin mining business.

9 h ago

MNSO (09896) spent $35,900 on December 12th to repurchase 7,356 shares.

Miniso Group (09896) announces that the company repurchased 7,356 shares for a total of $35,900 on December 12, 2025, at a repurchase price of $4.8725-$4.875 per share.

9 h ago

Yum China (09987) spent HKD 21.6724 million on December 12 to buy back 5.81 thousand shares.

China Everbright (09987) announced that the company spent 21.6724 million Hong Kong dollars on December 12, 2025 to repurchase 58,100 shares, with a repurchase price of 369.2-376 Hong Kong dollars per share.

9 h ago

E&P GLOBAL (01142) received a summons filed by Daily Loyal Limited to the Hong Kong High Court.

Energy and Energy Globally (01142) announced that on September 29, 2025, the company (as the defendant) received a summons filed by Daily Loyal Limited (the plaintiff) with the Hong Kong High Court (without a statement of claim), accusing the company of breaching the global settlement agreement entered into on October 25, 2024 (the lawsuit).

9 h ago

INNOCARE (09969): The phase IIb clinical trial of olokizumab in the treatment of systemic lupus erythematosus has achieved positive results and the phase III clinical trial has been initiated.

Nuocheng Jianhua (09969) announced that the Drug Evaluation Center (CDE) has approved the initiation of phase III clinical trials for the treatment of systemic lupus erythematosus (SLE) with Obrutinib. Building on the solid data from phase IIb clinical trials, the phase III study will evaluate a once daily dosing regimen of 75mg.

10 h ago

DUALITYBIO-B(09606) recommends adopting the 2025 stock plan.

Ying En Biological-B (09606) announced that on December 13, 2025, the board of directors of Ying En Biological (the Company, together with its subsidiaries collectively referred to as the Group) proposed to adopt the 2025 share plan, subject to approval by the Company's shareholders.

10 h ago

Cui Dongshu: Overall strong trend in the national automobile market in 2025, the popularity of new energy commercial vehicles is on the rise.

Driven by the national promotion fee policy, the automobile market maintains strong growth, and by 2025, the overall trend of the national automobile market remains strong, with a significant rebound in the truck market and the passenger car market.

10 h ago

Expand investment channels. Yangtze Optical Fibre and Cable Joint Stock (601869.SH) subsidiary, Changfei Capital, and EverProX Technologies intend to participate in the third phase of the Shanghai Merger and Acquisition Fund.

Changfei Optic (601869.SH) announced that its subsidiary, Changfei Capital Management Co., Ltd. (referred to as "Changfei Capital") and Chantsin Bond Technology Co., Ltd. (referred to as "Changxin Bond") intend to participate as limited partners in the establishment of the third phase of Shanghai M&A Fund. All partners of the third phase of Shanghai M&A Fund plan to subscribe for a total amount of 830 million yuan, with Changfei Capital planning to contribute 60 million yuan and Changxin Bond planning to contribute 40 million yuan.

11 h ago

Andon Health's US subsidiary, 4-IN-1 Check and 3-IN-1 Check products, have received pre-market notification from the US FDA.

Jiu'an Medical (002432.SZ) announced that the following products of its US subsidiary iHealth Labs Inc. (referred to as "iHealth USA") have received a pre-market notification from the US Food and Drug Administration (FDA):

11 h ago

Guangzhou Sie Consulting (300687.SZ): The intelligent scheduling software technology research and development project based on model simulation led by the company has received official approval for project establishment.

Announcement from SAI Information (300687.SZ): The company has received a notice from the national regulatory department regarding the establishment of a national major science and technology project for intelligent manufacturing systems and robots. The company's technology research project on intelligent scheduling software based on model simulation, which was led by the company, has been officially approved for establishment.

11 h ago

ApicHope Pharmaceutical Group (300723.SZ): The Qinxin clearing oral liquid has been approved as a protected traditional Chinese medicine variety.

Announcement from Yipin Hong (300723.SZ): The Quingxiang Qingle Oral Liquid of its wholly-owned subsidiary, Yipin Hong Biomedical Co., Ltd., has been approved as a national second-class protected variety of traditional Chinese medicine. Qingxiang Qingle Oral Liquid is used for dispelling wind-heat, clearing heat from the intestines, detoxifying, and relieving sore throats. It is mainly used in clinical practice for pediatric upper respiratory tract infections with symptoms of both exterior and interior heat.

11 h ago

ApicHope Pharmaceutical Group (300723.SZ) joint venture company, American Arthrosi, may be acquired.

Announcement from Yiping Hong (300723.SZ), the company's joint venture with the American company Arthrosi has received related agreement terms from Sobi USA. Sobi USA intends to acquire 100% equity of Arthrosi with an initial payment of 950 million US dollars (approximately 6.713 billion RMB) and up to 550 million US dollars (approximately 3.887 billion RMB) for clinical, registration, and sales milestone payments. The above transaction requires approval from Arthrosi shareholders, and after the transaction is completed, the company will no longer hold any ownership in Arthrosi.

11 h ago

GMT Eight

GMT Eight